Capital One Southcoast Reiterates a 'Neutral' on Geokinetics (GOK); Lowers PT & Estimates
Capital One Southcoast reiterates a Neutral on Geokinetics (NYSE Amex: GOK), lowers price target from $19 to $16.
Capital One analyst says, "Seismic acquisition demand slowed considerably in NA, and pricing is difficult. Int'l pricing and margins are still stable, but the main issue we have right now is the lack of visibility into 2010 and beyond. The company has not had any recent awards to replace run-off of
international work. Based on lower NAM margins and choppy 4Q09/1Q10, we are reducing our '09/'10 estimates from $0.30/$0.47 to ($0.04)/($0.23), rolling out '11 at ($0.12), and cutting our target price from $19 to $16 as we wait for news of GOK winning any potential int'l work."
To see more analyst ratings on GOK Click Here.
Geokinetics Inc. is providing seismic data acquisition services.
Capital One analyst says, "Seismic acquisition demand slowed considerably in NA, and pricing is difficult. Int'l pricing and margins are still stable, but the main issue we have right now is the lack of visibility into 2010 and beyond. The company has not had any recent awards to replace run-off of
international work. Based on lower NAM margins and choppy 4Q09/1Q10, we are reducing our '09/'10 estimates from $0.30/$0.47 to ($0.04)/($0.23), rolling out '11 at ($0.12), and cutting our target price from $19 to $16 as we wait for news of GOK winning any potential int'l work."
To see more analyst ratings on GOK Click Here.
Geokinetics Inc. is providing seismic data acquisition services.
You May Also Be Interested In
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Barclays Adjusts Estimates on Signet Jewelers (SIG) After Q2 Review
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Capital One SouthcoastSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
